STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Biovitrum (STO:BVT) today announced it has entered into a new agreement, effective August 8, 2007, with Wyeth (NYSE: WYE) to co-promote BeneFIX®, nonacog alfa (Recombinant Coagulation Factor IX) for hemophilia B, in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). With the exception of these countries, Wyeth markets BeneFIX® around the world.
